us national antiviral stockpile inadequate, page-3

Abobo,
I like your paasion. It add another persepctive.
It poses the questions as to:

What rights Biota has to publicise "Relenza" independently of GSK?

What right does Biota have to access (and publication) of sales/delvery/production figures other than at the end of each quarter?

Is it just a master/servant relationship?

Is Biota interested in positive publicity? eg IV treatment of critically ill patints etc etc

Should they employ a media person?

Do they monitor the media - including HotCopper who effectively provide a free monitoring service?

Regards
Kangaroo1